Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 9/20 | 0.51 |
| ▸ | LIPE | Q05469 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5543855 | 0.87 | NOTUM (0.49) | GPR119CHRM4 | |
| SCHEMBL22816478 | 0.87 | GPR119 (0.46) | GPR119CHRM4LIPEHTR2ACCR5 | |
| SCHEMBL31142600 | 0.84 | GPR119 (0.47) | GPR119 | |
| SCHEMBL5536857 | 0.83 | NPY5R (0.52) | GPR119 | |
| SCHEMBL28155287 | 0.83 | NPY5R (0.52) | GPR119 | |
| SCHEMBL594199 | 0.83 | GPR119 (0.46) | GPR119 | |
| SCHEMBL20046230 | 0.82 | USP2 (0.55) | GPR119 | |
| SCHEMBL23502124 | 0.81 | CHRM4 (0.54) | GPR119CHRM4LIPEFFAR4 | |
| SCHEMBL803440 | 0.81 | KDM4D (0.50) | GPR119 | |
| SCHEMBL10223318 | 0.80 | MAPT (0.46) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4472963-A1 | DGK TARGETING COMPOUNDS AND USES THEREOF | Arvinas Operations, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023150186-A1 | DGK TARGETING COMPOUNDS AND USES THEREOF | ARVINAS OPERATIONS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | GPR119 658/4885CHRM4 962/4885LIPE 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.